INTRODUCTION
Reproducing the complexity of tumor growth in pre-clinical models is important for mechanistic and functional studies of cancer biology. In non-small cell lung cancer (NSCLC), identifying biological targets for novel therapies and predictive markers for treatment selection will be of increasing importance in the future for individualized patient care. Its importance is further highlighted by the fact that NSCLC has the highest cancer mortality in the United States for both sexes with over 159,000 people dying from the disease in 2009 (1) . In patients, lung cancer biology is difficult to study longitudinally as invasive procedures are required to obtain tissue samples. Historically therefore, such biological studies have been conducted mainly on cancer cell lines grown in vitro or implanted into immune-compromised mice to form xenografts. Whilst cell lines are practical, reproducible and easy to manipulate, correlation of treatment results in these models with clinical results in patients has been suboptimal. While some studies have demonstrated some degree of correlation between in vitro and in vivo responses to treatment (2, 3) , others have reported considerable differences (4, 5) .
Considering that only a minority of primary tumors may form cell lines (6, 7) , that growth as a monolayer in vitro does not mirror the human tumor micro-environment or reproduce similar responses to treatment in vivo (4) , and that those tumors that do grow in vitro represent a subset of patients with poorer clinical outcome (7, 8) , other more clinically relevant models of NSCLC are required.
Formalin fixed and paraffin embedded (FFPE) tumor blocks of the primary tumors were reviewed histologically and multiple 1.5 mm cores were taken from areas of high tumor cellularity, using a tissue microarray corer (Beecher Instruments Inc).
Among 157 samples, 139 were available and suitable for DNA isolation. The cores were de-paraffinized by serial passages in xylene and ethanol solution, DNA was isolated as previously described (15) and subjected to mass spectrometric profiling for mutational sequence variants using the Sequenom Oncocarta panel (San Diego, CA) (16) . All mutations identified were verified in both the primary and xenograft tumors using standard PCR-sequencing methods. For MET, mutations we also investigated surrounding normal lung tissue to determine whether mutations detected in the primary tumor were present in normal tissues as well..
Statistical Analysis
Engraftment rate was correlated with clinico-pathological features, mutation status and disease-free survival (DFS). Fisher's exact test was used to determine the association of individual features with engraftment. DFS was calculated for patients with documented follow up of at least 12 months and was defined as time between surgery and relapse or death. DFS percentages were calculated using the Kaplan-Meier method (17) and the survival curves were compared with a log-rank test. Variables of interest (Table 1) . In multivariate analysis poor differentiation, squamous cell histology and larger T size were independently associated with increased rates of engraftment. (18), we sequenced the DNA of corresponding normal lung tissue from these patients for the same mutation. The results confirmed the presence of identical sequence variants indicating that these "mutations" were SNPs. Three tumors harbored more than one mutation. A significantly higher proportion of EGFR mutants were in the no-XG adenocarcinomas (p=0.027) and more KRAS mutants formed XG adenocarcinomas (p=0.054) (Figure 3 ). Other mutations were present infrequently, but equally between the two groups. The derived xenografts harbored the same mutations including samples with more than one mutation present in the primary tumor.
RESULTS

Engraftability of primary resected NSCLC
To determine whether the impact of engraftment on DFS was driven by mutational status, all patients whose tumors harbored mutations were excluded. As the MET sequence variants were SNPs, these samples were also counted as wild-type. In
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DISCUSSION
In this study, we have demonstrated that early stage NSCLCs that form xenografts in NOD-SCID mice reproduce with significant fidelity, the histological appearances of the patients' primary tumors. The xenograft take rates were higher for squamous cell carcinoma (65.2%) than adenocarcinoma (30.5%). The ability to engraft was also correlated with larger size of the primary tumors, poorer differentiation grade and KRAS mutations among adenocarcinomas. In contrast, adenocarcinomas that harbored sensitizing EGFR tyrosine kinase domain mutations demonstrated poor engraftability. Most importantly, patients whose tumors were able to form xenografts had significantly poorer disease free survival compared to patients whose tumors failed to engraft. All these results indicate that tumor engraftability is correlated with more aggressive biological and clinical behavior. Therefore, these primary xenografts are suitable models for mechanistic studies of NSCLC biology and as models to evaluate the efficacy of novel therapies that are being developed against NSCLC (19) . The 31.5% engraftment rate for adenocarcinomas is similar or only slightly higher than the success rate of establishing cell lines in culture (7, 8) . In contrast, the ability to establish xenografts in 64.4% of squamous cell carcinomas is significantly greater than the reported ability to culture and establish cell lines for this tumor type (3/18; 16% reported by Stevenson et al (8) and 1/25; 4% reported by Anderson et al (13) ). This difference in the ability to establish squamous cell xenografts was also observed by some (12, 20) but not all (13) researchers using a similar protocol to our own: however, the total number of squamous cell xenografts was only 16 in these studies combined.
Furthermore the differences we have described in patient outcome with engraftability were not seen in other PTXG studies (12) (13) (14) , which also may be reflective of the small numbers of patients included. Our observations suggest, though, that PTXGs may provide an excellent resource to study tumors from patients at high risk of relapse but also squamous cell tumors, a subgroup that has received limited attention in recent molecular studies.
The negative correlation of engraftablilty with EGFR TK domain mutations and positive correlation with KRAS mutations are in keeping with the observed prognostic value of these mutations in NSCLC patients (21, 22) . EGFR mutations are associated with an improved prognosis and KRAS mutations with poorer outcome (21). 
